

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Carfilzomib for treated multiple myeloma**

**Batch 40 and 47**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees and commentators highlighted that multiple myeloma is particularly prevalent in people of African and Caribbean family origin. They felt that a 'no' recommendation in final guidance would disproportionately impact on this group.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The increased prevalence of multiple myeloma in people of African and Caribbean family origin is a feature of the disease. The NICE guidance recommendations apply equally to all people and this potential equality issue is not related to protected characteristics, as defined by the Equalities Act, and so are not considered equality issues.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 28/04/2016